Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Titel:
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Auteur:
Platzbecker, Uwe Middeke, Jan Moritz Sockel, Katja Herbst, Regina Wolf, Dominik Baldus, Claudia D Oelschlägel, Uta Mütherig, Anke Fransecky, Lars Noppeney, Richard Bug, Gesine Götze, Katharina S Krämer, Alwin Bochtler, Tilmann Stelljes, Matthias Groth, Christoph Schubert, Antje Mende, Marika Stölzel, Friedrich Borkmann, Christine Kubasch, Anne Sophie von Bonin, Malte Serve, Hubert Hänel, Mathias Dührsen, Ulrich Schetelig, Johannes Röllig, Christoph Kramer, Michael Ehninger, Gerhard Bornhäuser, Martin Thiede, Christian